-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
Shallow Nanopore sequencing reveals genomic and epigenomic signatures of circulating tumor DNA in neuroendocrine tumor patients
- Share
- Tweet
- Share on Facebook
- Share
Poster titled: Prognostic Value of Circulating H3K27Me3-Nucleosomes In Newly Diagnosed Lung Cancer Patients
Benjamin P. Berman, Maria Ouzounova, Marie Piecyk, Christina Wheeler, Theresa K. Kelly, Lea Payen-Gay, Thomas Walter
Presented at CNAPS 2025
Related Articles
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields
